Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 2—February 2006
Research

Methicillin-resistant Staphylococcus aureus Clones, Western Australia

Geoffrey W. Coombs*†, Julie C. Pearson*, Frances G. O'Brien†, Ronan J. Murray*, Warren B. Grubb†, and Keryn J. Christiansen*†Comments to Author 
Author affiliations: *Royal Perth Hospital, Perth, Western Australia, Australia; †Curtin University of Technology, Bentley, Western Australia, Australia

Main Article

Table A1

Community MRSA antibiogram*. Download as PDF [61 KB, 3 pages].

ST
1
M
R
S
A
IV ST
129
M
R
S
A
IV ST
5
M
R
S
A
IV ST
45
M
R
S
A
V ST
8
M
R
S
A
IV ST
93
M
R
S
A
IV ST
75
M
R
S
A
IV ST
59
M
R
S
A
V ST
573
M
R
S
A
V ST
5
M
R
S
A
V ST
584
M
R
S
A
IV ST
59
M
R
S
A
IV ST
8
M
R
S
A
nov ST
583
M
R
S
A
IV ST
5
M
R
S
A
nov ST
609
M
R
S
A
IV ST
5
M
R
S
A
nov ST
577
M
R
S
A
V ST
45
M
R
S
A
IV ST
87
M
R
S
A
IV ST
575
M
R
S
A
IV ST
30
M
R
S
A
IV T
O
T
A
L %
β-lactam resistance only (44.05%)
O
1107
16
139
53
11
29
9




3


1

2

1

1
28
1400
44.05
β-lactam plus 1 non– β-lactam antimicrobial drug resistance (45.06%)
O, E
213
883
87
4
4
5




1






3

1


1201
37.79
O, F
132
1
3
1




2













139
4.37
O, C
29

4
1
1

















35
1.10
O, Tp
17
1
3

4

















25
0.79
O, Tc
10

1
1
1

















13
0.41
O, G


2






11












13
0.41
O, M
3





















3
0.09
O, R
1




















2
3
0.09
β-lactam plus 2 non–β-lactam antimicrobial drug resistance (9.44%)
O, E, F
179
4
1










1








185
5.82
O, E, C
3
18
16

6

















43
1.35
O, E, Tc
17
3


1


3














24
0.76
O, E, Tp
1
14




















15
0.47
O, G, Tp
8

2



















10
0.31
O, Tp, M
5

2



















7
0.22
O, E, R

5




















5
0.16
O, G, M
1

3



















4
0.13
O, E, M
1
1




















2
0.06
O, T, F
1












1








2
0.06
O, G, F
1





















1
0.03
O, G, C
1





















1
0.03
O, C, M












1









1
0.03
β-lactam plus 3 non–β-lactam antimicrobial drug resistance (0.98%)
O, E, TpR G
9

1

1

















11
0.35
O, E, G, M


4



















4
0.13
O, E, C, F
3





















3
0.09
O, Tc, F, M
1








2












3
0.09
O, E, Tp, M,
2
1




















3
0.09
O, E, C, M


1

1

















2
0.06
O, E, Tc, M,
1





















1
0.03
O, E, C, Tc


1



















1
0.03
O, E, C, Tp


1



















1
0.03
O, Tp, G, M
1





















1
0.03
O, Tc, G, M
1





















1
0.03
β-lactam plus 4 non–β-lactam antimicrobial drug resistance (0.38%)
O, E, Tc, F, M
6








1












7
0.22
O, E, C, Tc, G


2



















2
0.06
O, E, Tc, F, Tp









1












1
0.03
O, E, Tp, G, R




1

















1
0.03
O, E, F, M, G
1





















1
0.03
β-lactam plus 5 non–β-lactam antimicrobial drug resistance (0.09%)
O, E, C, F, M, G















1






1
0.03
O, E, C, F, M, Tp
1





















1
0.03
O, E, C, F, Tc, Tp
1





















1
0.03
TOTAL 1757 947 273 60 31 34 9 3 2 15 1 3 1 2 1 1 2 3 1 1 1 30 3178

*MRSA, methicillin-resistant Staphylococcus aureus; O, oxacillin; Tc, tetracycline; E, erythromycin; Tp, trimethoprim; C, ciprofloxacin; G, gentamicin; F, fusidic acid; R, rifampin; M, mupirocin; nov, novel.

Main Article

Page created: February 02, 2012
Page updated: February 02, 2012
Page reviewed: February 02, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external